Tirzepatide is administered once a week, and it is precisely this convenience that makes a dosing error especially insidious: the injected substance cannot be 'taken back', and it will keep acting for many more days. Cases of overdose are most often associated with incorrect measuring of the solution from vials, gray-market products and independent 'acceleration' of the regimen. The editorial team explains how an excess of the drug manifests, why it is dangerous and when emergency help is needed.
What is considered a tirzepatide overdose
Tirzepatide is an agonist of the receptors of two intestinal hormones, GIP and GLP-1, registered for the treatment of type 2 diabetes, obesity and, in some countries, obstructive sleep apnea. According to the official package insert, treatment starts with the minimum dose and increases gradually at intervals of no less than four weeks, and the maximum registered dose is 15 mg per week. Such slow titration is needed precisely so that the gastrointestinal tract has time to adapt.
An overdose is understood as any situation in which a person received more of the drug than was prescribed, or received it more often. This can be a single administration of an excessive dose, a repeated injection due to forgetfulness, the administration of two doses within an interval of a few days, or a sharp transition to a high dose without intermediate steps.
Since the symptoms of tirzepatide are largely dose-dependent, an 'overdose' in the clinical sense often looks like an intensified version of the usual side effects. The difference is that the intensity and duration of the manifestations can be such that the person is unable to drink and eat, and this already threatens dehydration and electrolyte imbalance.
Toxicologists and regulators pay attention to several typical error scenarios:
- incorrect measuring of the dose from vials of compounded or 'research' products (confusion between milligrams, milliliters and units on an insulin syringe);
- the unknown actual concentration in gray-market products;
- a repeated injection when a person does not remember whether they made it;
- independently skipping titration stages for the sake of a faster result;
- accidental administration of the drug to another person, in particular a child.
Why the long half-life matters
The tirzepatide molecule contains a fatty-acid chain that binds to blood albumin. Thanks to this, the half-life is about five days. For treatment this is an advantage - one injection per week. For an overdose it is a drawback: the excess of the drug will remain in the body for a long time, and the symptoms will not pass in a few hours.
The package insert directly emphasizes that in case of overdose the treatment should be supportive and take into account the long half-life. There is no specific antidote that would block the action of tirzepatide. Therefore doctors may recommend prolonged observation rather than a single examination.
In practice this means that a person's condition may worsen not immediately. The maximum concentration after subcutaneous administration is reached on average over several days, and gastrointestinal symptoms may build up gradually. The absence of symptoms in the first hours is not a guarantee that everything will be fine.
Another feature is the slowing of gastric emptying. This effect, characteristic of GLP-1 agonists, intensifies with an excessive dose and contributes to prolonged nausea, a feeling of fullness and vomiting. In addition, it can change the absorption of oral drugs taken during this period.
Signs and symptoms
The most frequent manifestations of a tirzepatide excess concern the digestive system. People describe pronounced nausea, repeated vomiting, pain and bloating in the abdomen, diarrhea or, conversely, constipation, a complete refusal of food. In clinical studies these symptoms occurred even at ordinary doses, especially during dose increases, but with an overdose they are more intense and longer-lasting.
As a result of fluid loss, signs of dehydration appear: thirst, dryness in the mouth, dizziness when standing up, weakness, a reduced amount of urine, a rapid heartbeat. For a person who is simultaneously restricting fluid or food, for example before a weigh-in, these manifestations develop faster.
In people who take insulin or sulfonylurea drugs, the main threat is hypoglycemia. Tirzepatide itself stimulates insulin secretion in a glucose-dependent manner, so on its own it rarely causes a severe drop in sugar. However, in combination with other glucose-lowering agents and in the absence of food, the risk increases significantly.
| Group of symptoms | Possible manifestations | What to pay attention to |
|---|---|---|
| Gastrointestinal | Nausea, vomiting, diarrhea, abdominal pain | Inability to retain fluid for more than a day |
| Dehydration | Thirst, dizziness, little urine, tachycardia | Confusion, loss of consciousness |
| Hypoglycemia | Sweating, trembling, hunger, irritability | Especially in combination with insulin |
| Pancreas | Severe pain in the upper abdomen radiating to the back | Possible acute pancreatitis |
| Gallbladder | Pain under the right rib, jaundice, fever | Possible cholecystitis, gallstones |
It is important not to write off prolonged symptoms as 'ordinary adaptation'. If after an injection vomiting has appeared that does not allow drinking water, or severe abdominal pain, this is a reason to seek medical help rather than to wait for the next week.
Serious complications
The most practically significant complication is acute kidney injury. The tirzepatide package insert warns that in patients with severe gastrointestinal reactions that led to dehydration, acute kidney injury and a worsening of chronic renal insufficiency have been reported. With an overdose, when vomiting and diarrhea are stronger, this mechanism becomes even more relevant.
The second serious risk is acute pancreatitis. In clinical studies it was recorded rarely, but the package insert requires discontinuing the drug if pancreatitis is suspected. A typical sign is severe constant pain in the upper abdomen, which can radiate to the back and be accompanied by vomiting.
Disturbances of the electrolyte balance as a result of prolonged vomiting and diarrhea - a decrease in potassium, sodium - can affect the work of the heart and muscles. In people with concomitant diseases of the heart, kidneys or diabetes, the consequences are sometimes more severe.
The risk of aspiration is worth mentioning separately. Because of the slowed gastric emptying, contents can remain in the stomach longer than expected. Regulators warn about the risk of pulmonary aspiration during general anesthesia or deep sedation in patients receiving GLP-1 agonists. Therefore, before any procedure under anesthesia, the doctor must be informed about the use of the drug, and all the more so about a possible overdose.
Finally, in the context of the gray market, product risks are added to the pharmacological ones: unknown concentration, impurities, non-sterility and even a different active substance in the vial. This makes the consequences unpredictable and complicates the work of doctors.
What to do and how to prevent it
If there is a suspicion that more of the drug was administered than prescribed, first of all you should contact the doctor managing the treatment, or a toxicology service or emergency service. It is important to name the drug, the actual or probable dose, the time of administration and other medications the person takes, especially insulin or sulfonylurea drugs.
You need to call an ambulance immediately in case of severe abdominal pain, vomiting that does not allow drinking, signs of severe dehydration, confusion, loss of consciousness or signs of hypoglycemia that do not pass after consuming carbohydrates. Treatment in such cases is supportive: restoration of fluid and electrolytes, glucose monitoring, antiemetics and observation.
You should not 'correct' an overdose on your own. You should not induce vomiting, take laxatives or skip subsequent medications without coordination with a doctor. The decision about the next scheduled injection is also made by the doctor, taking into account the person's condition.
Prevention largely comes down to discipline and the quality of the drug:
- use only registered drugs from a pharmacy with a prescription;
- follow the titration scheme determined by the doctor, without independent 'accelerations';
- record the date and dose of each injection in a calendar or app;
- store the drug in a place inaccessible to children;
- when working with vials, clarify with the doctor or pharmacist how to correctly measure the volume.
Editorial conclusions
A tirzepatide overdose rarely looks dramatic in the first hours, but because of a half-life of about five days its consequences can develop and last for many days. There is no specific antidote, so treatment comes down to support and observation.
The main threats are severe dehydration with a risk of acute kidney injury, hypoglycemia when combined with insulin or sulfonylurea, pancreatitis and complications from the gallbladder.
Most such situations can be prevented: use only pharmacy drugs, follow the prescribed regimen and do not experiment with doses for the sake of faster weight loss.
We also recommend reading our materials on the history of tirzepatide, on the interaction of GLP-1 agonists with other drugs, and on the tests that are monitored during therapy.
References
- Eli Lilly and Company. Mounjaro (tirzepatide) injection: prescribing information. U.S. Food and Drug Administration.
- Eli Lilly and Company. Zepbound (tirzepatide) injection: prescribing information. U.S. Food and Drug Administration.
- European Medicines Agency. Mounjaro (tirzepatide): summary of product characteristics. EMA.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
Andriy Melnyk
A strength-sports coach and author of programs for beginner and intermediate levels. Writes about training planning.
